News stories about Regulus Therapeutics (NASDAQ:RGLS) have been trending somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.5375635795078 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Several analysts have issued reports on RGLS shares. Zacks Investment Research lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine lowered Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Wedbush restated an “ourperform” rating and issued a $6.00 price objective on shares of Regulus Therapeutics in a research note on Tuesday, June 13th. BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics and gave the company a “hold” rating in a research note on Monday, June 12th. Finally, Chardan Capital dropped their price objective on Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating on the stock in a research note on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Regulus Therapeutics has a consensus rating of “Hold” and an average price target of $3.58.

Shares of Regulus Therapeutics (RGLS) traded up 5.8839% during trading on Wednesday, hitting $1.1859. The stock had a trading volume of 1,199,772 shares. The company’s 50 day moving average price is $0.98 and its 200 day moving average price is $1.23. The company’s market capitalization is $123.08 million. Regulus Therapeutics has a 52 week low of $0.79 and a 52 week high of $3.65.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Analysts predict that Regulus Therapeutics will post ($1.02) earnings per share for the current year.

In other news, Director William H. Rastetter acquired 274,725 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, for a total transaction of $249,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph P. Hagan acquired 219,780 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the purchase, the insider now owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 549,450 shares of company stock worth $500,000. 4.80% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Regulus Therapeutics (RGLS) Stock Price” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-regulus-therapeutics-rgls-stock-price.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Stock Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related stocks with our FREE daily email newsletter.